Evidence map›Paper›PMID 41953960›Full record

ArticleAdvanced healthcare materials2026

Bifunctional Surfaces With Immobilized Antibodies and Bioactive Peptides Mediate Selective Capture and Proliferation of Endothelial Colony-Forming Cells.

Hugo A Level, Marc-Antoine Campeau, Mohamed A Elkhodiry, Gaétan Laroche, Jean-François Tanguay, Corinne A Hoesli

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hugo A LevelDepartment of Chemical Engineering, McGill University, Montreal, Canada.ORCID https://orcid.org/0009-0008-1432-7465
Marc-Antoine CampeauDepartment of Chemical Engineering, McGill University, Montreal, Canada.ORCID https://orcid.org/0000-0001-7483-2094
Mohamed A ElkhodiryDepartment of Chemical Engineering, McGill University, Montreal, Canada.ORCID https://orcid.org/0000-0001-7771-7067
Gaétan LarocheCentre de Recherche du CHU de Québec & Département de Génie des Mines, des, Matériaux et de la Métallurgie, Université Laval, Québec, Canada.ORCID https://orcid.org/0000-0003-0661-628X
Jean-François TanguayMontreal Heart Institute, University of Montreal, Montreal, Canada.ORCID https://orcid.org/0009-0001-7258-3191
Corinne A HoesliDepartment of Chemical Engineering, McGill University, Montreal, Canada.ORCID https://orcid.org/0000-0002-5629-7128

Funding

CIHR CIHRDV2-197669CIHR CIHR MOP 142285Fonds de Recherche du Québec - Nature et Technologies 366519Heart and Stroke Foundation of Canada G-25-0041715Natural Sciences and Engineering Research Council of Canada RGPIN-2020-05877
6 · The paper itself

Abstract

Endothelial colony-forming cells (ECFCs) are of significant interest in vascular biomaterials engineering and cell-based therapies for cardiovascular diseases. Efficient isolation and expansion of ECFCs on polymeric surfaces either in vitro or in situ in the case of implants could significantly advance ECFC-based therapies. We present a novel bifunctional surface modification strategy combining oriented antibodies and extracellular matrix-derived peptides to selectively capture ECFCs on surfaces and then mediate firm adhesion, spreading and proliferation. Studies were conducted with anti-CD309 antibodies and custom RGD peptides, previously shown to respectively enable ECFC capture and clonal expansion. To aid in oriented antibody immobilization on surfaces while modulating antibody-RGD surface concentrations, Fc-binding peptides and RGD peptides were co-immobilized on aminated surfaces using click chemistry, followed by affinity-mediated antibody immobilization. Bifunctional anti-CD309 + RGD surfaces selectively captured ECFCs from a mixture with peripheral blood mononuclear cells in dynamic conditions. The presence of RGD peptides significantly enhanced cell spreading and proliferation, leading to additive effects on surface coverage under flow. Proof-of-concept studies demonstrated successful adaptation to 3D polystyrene microcarriers, showcasing potential scalability for clinical-grade cell production. The surface modification scheme provides a versatile and clinically translatable platform for advancing ECFC-based regenerative therapies.

Indexed as

Antibodies, ImmobilizedEndothelial CellsEndothelial Progenitor CellsOligopeptidesPeptidesCell AdhesionCell ProliferationCells, CulturedHumansSurface PropertiesAntibodies, Immobilizedarginyl-glycyl-aspartic acidOligopeptidesPeptidesantibodiescell capturecellular therapyendothelial colony‐forming cellsextracellular matrixmicrocarrierspeptidessurface modification

Identifiers

PMID41953960
PMCPMC13241468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.